Advanced, Metastatic Breast Cancer
6
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
9 treatments under study, led by Letrozole
Research Leaders
5 sponsors active, led by Novartis Pharmaceuticals
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
67%
4 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Research Network
Common Treatments
- Letrozole3
- Ribociclib3
- Goserelin2
- Letrozole Sie Ribociclib Oral Placebo1
- Tamoxifen1
Active Sponsors
- Novartis Pharmaceuticals3
- European Institute of Oncology1
- Rovi Pharmaceuticals Laboratories1
- AstraZeneca1
- Laboratorios Farmaceuticos Rovi S.A.1
Top Investigators
Istituto Europeo di Oncologia
Related Conditions
- Hrpositive Her2negative Inoperable Locally Advanced Or Metastatic Breast Cancer1